Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.</p>

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Thematic (Sector/Industry)

<div class="content-remarks"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/074/094/original/PA%20Coverage_20181228.PNG?1545990481" class="editor-image img-responsive" data-smartkarma-image-id="74094"></figure></div><div class="content-caption">Source: Pathology Associates research</div><p>                                                                                                                                                                                                                                                                        `                        </p>

Source: Pathology Associates research                                                                                                                                                                                                                                                                        `                        

Equity Bottom-Up

<p><strong>Key Drivers</strong></p><ul>
<li>MN-166 (ibudilast, PhIIb) and MN-001 (tipelukast, PhII) together targeting potential market worth $3-4b.</li>
<li>Positive MN-166 (ibudilast) Ph IIb data in PMS and ALS led increased probability of success (overall MS market potential -$20b+ , ibudilast competitive potential - $1.5-3b)</li>
<li>Potential revenue contribution from FY22e</li>
</ul>

Key Drivers
MN-166 (ibudilast, PhIIb) and MN-001 (tipelukast, PhII) together targeting potential market worth $3-4b.
Positive MN-166 (ibudilast) Ph IIb data in PMS and ALS led increased probability of success (overall MS market potential -$20b+ , ibudilast competitive potential - $1.5-3b)
Potential revenue contribution from FY22e


United States

MediciNova, Inc. operates as a biopharmaceutical company. The Company acquires and develops small molecule therapeutics for the treatment of asthma and COPD, progressive multiple sclerosis, neuropathic pain, methamphetamine addiction, interstitial cystitis, and solid tumor cancers. MediciNova offers its products to the healthcare industry with a focus on the Unites States market.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MediciNova (MNOV US)

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the...

Vermilion Research

Japan Pharma - Top Picks (28 Dec 2018)

...

Dion Stéfan Büchner M.D., FCAP

Investment Thesis and Valuation

Key Drivers MN-166 (ibudilast, PhIIb) and MN-001 (tipelukast, PhII) together targeting potential market worth $3-4b. Positive MN-166 (ibudilast) Ph...

Dion Stéfan Büchner M.D., FCAP

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)